Literature DB >> 34269483

Cytosolic GDH1 degradation restricts protein synthesis to sustain tumor cell survival following amino acid deprivation.

Jialiang Shao1, Tiezhu Shi1, Hua Yu2,3, Yufeng Ding1, Liping Li3, Xiang Wang1, Xiongjun Wang2,3.   

Abstract

The mTORC1 pathway plays key roles in regulating various biological processes, including sensing amino acid deprivation and driving expression of ribosomal protein (RP)-coding genes. In this study, we observed that depletion of glutamate dehydrogenase 1 (GDH1), an enzyme that converts glutamate to α-ketoglutarate (αKG), confers resistance to amino acid deprivation on kidney renal clear cell carcinoma (KIRC) cells. Mechanistically, under conditions of adequate nutrition, GDH1 maintains RP gene expression in a manner dependent on its enzymatic activity. Following amino acid deprivation or mTORC1 inhibition, GDH1 translocates from mitochondria to the cytoplasm, where it becomes ubiquitinated and degraded via the E3 ligase RNF213. GDH1 degradation reduces intracellular αKG levels by more than half and decreases the activity of αKG-dependent lysine demethylases (KDMs). Reduced KDM activity in turn leads to increased histone H3 lysine 9 and 27 methylation, further suppressing RP gene expression and preserving nutrition to support cell survival. In summary, our study exemplifies an economical and efficient strategy of solid tumor cells for coping with amino acid deficiency, which might in the future be targeted to block renal carcinoma progression.
© 2021 The Authors.

Entities:  

Keywords:  GDH1; amino acid deprivation; kidney cancer; ribosomes; αKG

Mesh:

Substances:

Year:  2021        PMID: 34269483      PMCID: PMC8521317          DOI: 10.15252/embj.2020107480

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   14.012


  72 in total

Review 1.  Autophagy and metabolism.

Authors:  Joshua D Rabinowitz; Eileen White
Journal:  Science       Date:  2010-12-03       Impact factor: 47.728

2.  Alpha helical structures in the leader sequence of human GLUD2 glutamate dehydrogenase responsible for mitochondrial import.

Authors:  Dimitra Kotzamani; Andreas Plaitakis
Journal:  Neurochem Int       Date:  2012-06-16       Impact factor: 3.921

3.  Associations Between Loss of ARID1A Expression and Clinicopathologic and Genetic Variables in T1 Early Colorectal Cancer.

Authors:  Yoshihiro Kishida; Takuma Oishi; Takashi Sugino; Akio Shiomi; Kenichi Urakami; Masatoshi Kusuhara; Ken Yamaguchi; Yuko Kitagawa; Hiroyuki Ono
Journal:  Am J Clin Pathol       Date:  2019-09-09       Impact factor: 2.493

4.  Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations.

Authors:  Stefan Gross; Rob A Cairns; Mark D Minden; Edward M Driggers; Mark A Bittinger; Hyun Gyung Jang; Masato Sasaki; Shengfang Jin; David P Schenkein; Shinsan M Su; Lenny Dang; Valeria R Fantin; Tak W Mak
Journal:  J Exp Med       Date:  2010-02-08       Impact factor: 17.579

5.  Real-time assay for testing components of protein synthesis.

Authors:  Gabriel Rosenblum; Chunlai Chen; Jaskiran Kaur; Xiaonan Cui; Yale E Goldman; Barry S Cooperman
Journal:  Nucleic Acids Res       Date:  2012-03-14       Impact factor: 16.971

6.  The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.

Authors:  Patrick S Ward; Jay Patel; David R Wise; Omar Abdel-Wahab; Bryson D Bennett; Hilary A Coller; Justin R Cross; Valeria R Fantin; Cyrus V Hedvat; Alexander E Perl; Joshua D Rabinowitz; Martin Carroll; Shinsan M Su; Kim A Sharp; Ross L Levine; Craig B Thompson
Journal:  Cancer Cell       Date:  2010-02-18       Impact factor: 38.585

7.  Regulation of mitochondrial biogenesis in erythropoiesis by mTORC1-mediated protein translation.

Authors:  Xin Liu; Yuannyu Zhang; Min Ni; Hui Cao; Robert A J Signer; Dan Li; Mushan Li; Zhimin Gu; Zeping Hu; Kathryn E Dickerson; Samuel E Weinberg; Navdeep S Chandel; Ralph J DeBerardinis; Feng Zhou; Zhen Shao; Jian Xu
Journal:  Nat Cell Biol       Date:  2017-05-15       Impact factor: 28.824

Review 8.  mTORC1 as the main gateway to autophagy.

Authors:  Yoana Rabanal-Ruiz; Elsje G Otten; Viktor I Korolchuk
Journal:  Essays Biochem       Date:  2017-12-12       Impact factor: 8.000

9.  Genomic analysis of liver cancer unveils novel driver genes and distinct prognostic features.

Authors:  Xiangchun Li; Weiqi Xu; Wei Kang; Sunny H Wong; Mengyao Wang; Yong Zhou; Xiaodong Fang; Xiuqing Zhang; Huanming Yang; Chi H Wong; Ka F To; Stephen L Chan; Matthew T V Chan; Joseph J Y Sung; William K K Wu; Jun Yu
Journal:  Theranostics       Date:  2018-02-12       Impact factor: 11.556

10.  R-2HG Exhibits Anti-tumor Activity by Targeting FTO/m6A/MYC/CEBPA Signaling.

Authors:  Rui Su; Lei Dong; Chenying Li; Sigrid Nachtergaele; Mark Wunderlich; Ying Qing; Xiaolan Deng; Yungui Wang; Xiaocheng Weng; Chao Hu; Mengxia Yu; Jennifer Skibbe; Qing Dai; Dongling Zou; Tong Wu; Kangkang Yu; Hengyou Weng; Huilin Huang; Kyle Ferchen; Xi Qin; Bin Zhang; Jun Qi; Atsuo T Sasaki; David R Plas; James E Bradner; Minjie Wei; Guido Marcucci; Xi Jiang; James C Mulloy; Jie Jin; Chuan He; Jianjun Chen
Journal:  Cell       Date:  2017-12-14       Impact factor: 66.850

View more
  3 in total

1.  Glutamate regulates gliosis of BMSCs to promote ENS regeneration through α-KG and H3K9/H3K27 demethylation.

Authors:  Mengke Fan; Huiying Shi; Hailing Yao; Weijun Wang; Yurui Zhang; Chen Jiang; Rong Lin
Journal:  Stem Cell Res Ther       Date:  2022-06-17       Impact factor: 8.079

2.  GLUD1 suppresses renal tumorigenesis and development via inhibiting PI3K/Akt/mTOR pathway.

Authors:  Lei Wang; Zhiyu Fang; Peixiang Gao; Junfang Zheng
Journal:  Front Oncol       Date:  2022-09-20       Impact factor: 5.738

3.  Cytosolic GDH1 degradation restricts protein synthesis to sustain tumor cell survival following amino acid deprivation.

Authors:  Jialiang Shao; Tiezhu Shi; Hua Yu; Yufeng Ding; Liping Li; Xiang Wang; Xiongjun Wang
Journal:  EMBO J       Date:  2021-07-16       Impact factor: 14.012

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.